For more than 75 years, Janssen has been helping improve health around the world. From early discovery to distribution, patient access and education, we continuously search for ways to deliver quality and value. Advancing the best science into a transformational medicine is just the first step to helping people lead healthier lives. Janssen are committed to making a meaningful difference in global public health. Our overarching aspiration is to help more people in more places have access to our medicines and to sustainable, effective healthcare solutions.
Neuropsychiatric diseases and pain conditions have a staggering effect on people and society. An estimated 44 million people worldwide have dementia; schizophrenia affects approximately 24 million people globally; more than 350 million people around the world have depression, and 1.5 billion people in the world suffer from chronic pain.
The Janssen Neuroscience Therapeutic Area is deeply committed to patients with these conditions and to the health care professionals and loved ones who care for them. Our research priorities are Alzheimer’s disease, Mood Disorders, Schizophrenia and Pain. Across neuroscience, our researchers are exploring the emerging science of synaptic plasticity and cellular resilience, with an emphasis on developing novel therapeutics for the treatment of severe mood disorders and neurodegenerative dementias.
We are enhancing the Janssen Neuroscience culture of innovation and bringing forth new treatments for those in need. We are united and energized by one mission—discovering, developing and delivering differentiated medicines that address the most serious unmet medical needs of our time.
Our strategy is to harness the best science in the world, whether from our own laboratories or through strategic relationships and collaborations with academia, biotech and other pharmaceutical companies.
We share a deep commitment to the communities in which we live and work. This passion is expressed through sponsorship of scientific symposia, educational programs about brain disorders, development of global mental health programs, and other scholarly and community-based activities. We are also strongly focused on projects that break down global stigma about brain disorders. The Neuroscience TA also is leading scientific research into integrated solutions and informatics, moving away from only single pharmacologic treatments and toward integrated health care solutions.
With their extensive experience in preclinical and clinical neuroscience, the experimental medicine team members will contribute time and scientific expertise to work packages 2, 4, 5 and 6.